Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study

Diabetologia

Volumn 51, Issue 7, 2008, Pages 1127-1134

  Sandbaek, A ^a   Griffin, S J ^b   Rutten, G ^c   Davies, M ^d   Stolk, R ^e   Khunti, K ^d   Borch Johnsen, K ^a,f   Wareham, N J ^b   Lauritzen, T ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f STENO DIABETES CENTER   (Denmark)

Author keywords

Coronary heart disease; Diagnosis; General practice; Screening; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SCREENING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CORONARY DISEASE; DENMARK; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 44749091012     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-1013-0     Document Type: Article

References (32)

1. Laakso M, Lehto S (1997) Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5:294-315
2. Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-819
3. Spijkerman AM, Adriaanse MC, Dekker JM et al (2002) Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 25:1784-1789
4. UK Prospective Diabetes Study 6 (1990) Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1-11
5. UK Prospective Diabetes Study (UKPDS) (1991) VIII. Study design, progress and performance. Diabetologia 34:877-890
6. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
7. Guillausseau PJ, Massin P, Charles MA et al (1998) Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabet Med 15:151-155
8. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240
9. Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 Study. Diabetes Care 26:2335-2340
10. Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med 12:30-35
11. Glumer C, Yugun M, Griffin S et al (2006) What determines the cost-effectiveness of diabetes screening? Diabetologia 49:1536-1544
12. Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762
13. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713
14. Lindholm LH, Ibsen H, Dahlof B et al (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010
15. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
17. Wareham NJ, Griffin SJ (2001) Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ 322:986-988
18. Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A (2003) Screening for type 2 diabetes-should it be now? Diabet Med 20:175-181
19. Sandbaek A, Lauritzen T, Borch-Johnsen K, Mai K, Christiansen JS (2005) The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of type 2 diabetes: a population-based screening study. Diabet Med 22:1173-1177
20. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6-S11
21. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 Study. Diabetes Care 27:727-733
22. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ (1997) Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 20:491-496
23. Janssen PG, Gorter KJ, Stolk RP, Rutten GE (2007) Low yield of population-based screening for type 2 diabetes in the Netherlands. The ADDITION Netherlands Study. Fam Pract 24:555-561
24. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 16:164-171
25. Alberti KG, Zimmet PZ (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. WHO, Geneva
26. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
27. Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46:1417-1432
28. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671-679
29. Little RJA, Rubin DB (2002) Statistical analysis with missing data, 2nd edn. Wiley, New York
30. Song SH, Brown PM (2004) Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21:238-245
31. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 22:554-562
32. Bhopal R, Unwin N, White M et al (1999) Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi and European origin populations: cross sectional study. BMJ 319:215-220